The endocannabinoid system: A new approach to control cardiovascular disease

Clinical Cornerstone

Volumn 7, Issue 2-3, 2005, Pages 17-26

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LIGAND;

ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE CONTROL; DRUG TARGETING; DYSLIPIDEMIA; FOOD INTAKE; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; RECEPTOR BLOCKING; REGULATORY MECHANISM; RISK REDUCTION; THROMBOSIS; TISSUE METABOLISM;

APPETITE REGULATION; CARDIOVASCULAR DISEASES; ENDOCANNABINOIDS; HISTORY, 20TH CENTURY; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 32144447596     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(05)80064-X     Document Type: Article

References (51)

1. Cota D. Marsicano G. Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest. 112 2003 423-431
2. Gomez R. Navarro M. Ferrer B. et al. A peripheral mechanism for CBI cannabinoid receptor-dependent modulation of feeding J Neurosci. 22 2002 9612-9617
3. Di Marzo V. Melck D. Bisogno T. De Petrocellis L. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action Trends Neurosci. 21 1998 521-528
4. Di Marzo V. Fontana A. Cadas H. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 1994 686-691
5. Bensaid M. Gary-Bobo M. Esclangon A. et al. The cannabinoid CB1 receptor antagonist SR 141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells Mol Pharmacol 63 2003 908-914
6. Matsuda L.A. Molecular aspects of cannabinoid receptors Crit Rev Neurobiol 11 1997 143-166
7. Gaoni Y. Mecbonlam R. Isolation, structure and partial synthesis of an active constituent of hashish J Am Chem Soc. 86 1964 1646-1647
8. Devane W.A. Dysarz F.A. III Johnson M.R. Determination and characterization of a cannabinoid receptor in rat brain Mol Pharmacol 34 1988 605-613
9. Matsuda L.A. Lolait S.J. Brownstein M.J. et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561-564
10. Gerard C.M. Mollereau C. Vassart G. Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem J 279 1991 129-134
11. Devane W.A. Hanus L. Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946-1949
12. Munro S. Thomas K.L. Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61-65
13. Rinaldi-Carmona M. Barth F. Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240-244
14. Sugiura T. Kondo S. Sukagawa A. et al. 2-Arachidonoyl-glycerol: A possible endogenous cannabinoid receptor ligand in brain Biochem Biophys Res Commun. 215 1995 89-97
15. Shen M. Piser T.M. Seybold V.S. Thayer S.A. Cannabinoid receptor agonists inhibit glutamateric synaptic transmission in rat hippocampal cultures J Neurosci. 16 1996 4322-4334
16. Ledent C. Valverde O. Cossu G. et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401-404
17. Liu J. Gao B. Mirshahi F. et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells Biochem J. 346 2000 835-840
18. Cohen C. Perrault G. Voltz C. et al. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451-463
19. Bonz A. Laser M. Kullmer S. et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle J Cardiovasc Pharmacol. 41 2003 657-664
20. Ravinet Trillou C. Arnone M. Delgorge C. et al. Anti-obesity effect of SR 141716, a CB1 receptor antagonist, in diet-induced obese mice Am J Physiol Regul Integr Comp Physiol 284 2003 R345-R353
21. Di Marzo V. Bifulco M. De Petrocellis L. The endocannabinoid system and its therapeutic exploitation Nat Rev Drug Discov. 3 2004 771-784
22. Van Gaal L.F. Rissanen A.M. Scheen A.J. et al. RIO-Europe Study Group Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study Lancet 365 2005 1389-1397
23. Wilson R.I. Nicoll R.A. Endocannabinoid signaling in the brain Science 296 2002 678-682
24. Pagotto U. Vicennati V. Pasquali R. The endocannabinoid system and the treatment of obesity Ann Med 37 2005 270-275
25. Kirkham T.C. Williams C.M. Fezza F. Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by2-arachidonoyl glycerol Br J Pharmacol 136 2002 550-557
26. Cohen C. Kodas E. Griebel G. CB1 Receptor antagonists for the treatment of nicotine addiction Pharmacol Biochem Behav. 81 2005 387-395
27. Williams C.M. Kirkham T.C. Anandamide induces over-eating: Mediation by central cannabinoid (CB1) receptors Psychopharmacology (Berl) 143 1999 315-317
28. Beal J.E. Olson R. Laubenstein L. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS J Pain Symptom Manage. 10 1995 89-97
29. Jamshidi N. Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats Br J Pharmacol 134 2001 1151-1154
30. Croci T. Manara L. Aureggi G. et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum Br J Pharmacol 125 1998 1393-1395
31. Reidelberger R.D. Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats Am J Physiol 263 1992 R1354-R1358
32. Engeli S. Bohnke J. Feldpausch M. et al. Activation of the peripheral endocannabinoid system in human obesity Diabetes 54 2005 2838-2843
33. Gimeno R.E. Klaman L.D. Adipose tissue as an active endocrine organ: Recent advances Curr Opin Pharmacol 5 2005 122-128
34. Diez J.J. Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease Eur J Endocrinol. 148 2003 293-300
35. Hu E. Liang P. Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity J Biol Chem. 271 1996 10697-10703
36. Arita Y. Kihara S. Ouchi N. et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochem Biophys Res Commun. 257 1999 79-83
37. Fruebis J. Tsao T.S. Javorschi S. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc Natl Acad Sci USA 98 2001 2005-2010
38. Weyer C. Funahashi T. Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia J Clin Endocrinol Metab. 86 2001 1930-1935
39. Hotamisligil G.S. Shargill N.S. Spiegelman B.M. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance Science 259 1993 87-91
40. Cote M. Mauriege P. Bergeron J.et al. Adiponectinemia in visceral obesity: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men J Clin Endocrinol Metab. 90 2005 1434-1439
41. Pouliot M.C. Despres J.P. Nadeau A. et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels Diabetes 41 1992 826-834
42. Yusuf S. Hawken S. Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study Lancet 364 2004 937-952
43. Dagenais G.R. Yi Q. Mann J.F. et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease Am Heart J. 149 2005 54-60
44. Despres J.P. Lemieux I. Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients BMJ 322 2001 716-720
45. Sharma A.M. Adipose tissue: A mediator of cardiovascular risk Int J Obes Relat Metab Disord 26 Suppl 4 2002 S5-S7
46. Ford E.S. Mokdad A.H. Giles W.H. Trends in waist circumference among U.S. adults Obes Res. 11 2003 1223-1231
47. Okosun I.S. Chandra K.M. Boev A. et al. Abdominal adiposity in U.S. adults: Prevalence and trends, 1960-2000 Prev Med. 39 2004 197-206
48. Di Marzo V. Bifulco M. De Petrocellis L. The endocannabinoid system and its therapeutic exploitation Nat Rev Drug Discov. 3 2004 771-784
49. Horvath T.L. Endocannabinoids and the regulation of body fat: The smoke is clearing J Clin Invest 112 2003 323-326
50. Van Gaal L.F. Rissanen A.M. Scheen A.J. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study Lancet 365 2005 1389-1397
51. Després J.P. Golay A. Sjöström L. Rimonabant in Obesity-Lipids Study Group Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med. 353 2005 2121-2134